Editor’s note: This is general educational information about how research ratings and target prices are produced and disclosed. It is not investment advice and contains no recommendation about any security. The rules and figures below are taken from the official documents listed at the end.
Analysis: Targets Are Testable, and the Rules Say How
The useful distinction is not between good analysts and bad ones. It is between a number whose derivation is disclosed and a number that is quoted without it. Rule 2241 assumes the second case is the problem and legislates against it in three ways: it attaches the valuation method to the target, it attaches the firm’s own track record to the report through the three-year graph, and it attaches the firm’s rating distribution so the label can be read against the firm’s habits rather than against an assumed neutral scale.
That structure suggests what a revision actually signals. A target changes either because the method’s inputs changed, because the method itself changed, or because the rating changed. The first is ordinary and usually explained in the report’s forecast section. The second is more significant, because a switch of method is a statement that the previous frame no longer described the business. The report has to explain the valuation method used, so the two cases are separable by anyone reading past the headline.
The conflict disclosures answer a different question. A firm that has received non-investment-banking compensation from the subject company in the previous 12 months, or that is making a market in the stock, is not thereby wrong, but the report has to say so, and the 10 day post-IPO restriction exists because that particular overlap was judged too close to manage by disclosure alone.
The Korean merger amendment lands on the same underlying issue from the issuer’s side. Where a valuation determines what minority shareholders receive, Korea has moved from a single observable input, the market price, to a composite of share price, asset value and earning values, with a board opinion on the appropriateness of the price and an external appraisal attached. Both regimes are converging on the same requirement: publish the number, and publish the reasoning that produced it, in a form someone else can check.
What the documents say
A target price is a number with a document attached. Most of the argument about whether targets are useful ignores the document, which is where the rules require the analyst to say what method produced the number, what could stop it being reached, and what business relationship exists between the firm publishing it and the company being valued. Reading the target alone discards almost everything the regulation was written to surface.
The Number Has to Come With a Method
FINRA Rule 2241 sets the standard for research reports in the United States. It requires that any recommendation, rating or target price have a reasonable basis and be accompanied by a clear explanation of any valuation method used and a fair presentation of the risks that may impede achievement of the recommendation, rating or target price.
Each of those three obligations does separate work. A reasonable basis is the analytical floor. The explanation of the valuation method tells a reader whether they are looking at a multiple applied to a forecast, a discounted cash flow, an asset-based figure, or something else, which determines what would have to change for the target to change. And the fair presentation of risks forces the report to describe the paths on which the number fails, which is the part a summary headline always drops.
The Record of Past Targets Travels With the Report
A target price published in isolation is unfalsifiable. Rule 2241 makes the history visible. Where a research report contains a rating or target price and the firm has assigned one to that security for at least one year, the report must include a line graph of the security’s daily closing prices covering the period during which any rating or target price was assigned, or a three-year period, whichever is shorter. The graph must indicate the dates on which each rating or target was assigned or changed, and depict each rating or target set on those dates.
Alongside that, and irrespective of the rating system a firm uses, each report containing a rating must state the percentage of all the securities it rates that it would place in each of its buy, hold and sell categories. That single disclosure is the calibration tool. A buy label from a firm whose distribution leans heavily that way carries different information from the same word at a firm with a flatter spread.
Conflicts Are Disclosed by Category, Not by Assertion
The rule enumerates the relationships that must appear in the report at publication. They include whether the firm or its affiliates received compensation from the subject company for products or services other than investment banking in the previous 12 months, whether the subject company is or has been a client during the preceding 12-month period and what type of services were provided, whether the firm was making a market in the security at the time of publication, and any other material conflict known to the analyst or to an associated person able to influence the report’s content.
Structural separation backs the disclosure. Firms must have written policies covering the preparation, content and distribution of research reports, must prohibit prepublication review, clearance or approval of research reports by people engaged in investment banking, and must restrict or prohibit such review by others not directly responsible for the report, apart from legal and compliance personnel. Where sections of a draft are shown to non-research personnel or to the subject company, those sections must not contain the research summary, the rating or the target price, and if the research department then intends to change the proposed rating or target it must obtain written authorisation from legal or compliance, with drafts and the final version retained for three years.
There are timing restrictions as well. Publication is barred for a minimum of 10 days following an initial public offering where the firm participated as an underwriter or dealer. Smaller firms get relief from some of the structural provisions: those that over the previous three years averaged 10 or fewer investment banking transactions a year as manager or co-manager and generated $5 million or less in gross investment banking revenues from them are exempt from several paragraphs, though they must still build information barriers insulating analysts from pressure.
A separate SEC rule attaches the analyst’s own name to the number. Under Regulation AC, a broker or dealer that publishes a research report to a U.S. person must include a certification by the research analyst attesting that all of the views expressed in the report accurately reflect that analyst’s personal views about the subject securities, and either that no part of the analyst’s compensation was tied to the specific recommendations in the report or, if it was, disclosing the source, amount and purpose of that compensation. The target price is not just modeled; it is signed.
Korea Is Regulating Valuation From a Different Direction
Korea’s recent intervention on valuation targets corporate transactions rather than research, and it is instructive because it forces the same question into a filing. On August 20, 2026 the National Assembly passed an amendment to the Financial Investment Services and Capital Markets Act changing how merger value is calculated for listed companies. Under the previous framework the merger price between listed companies and their affiliates was determined by a market value approach, which the Financial Services Commission said had led controlling shareholders seeking favourable terms to time transactions for periods when an affiliate’s market value sat below fair value, suppressing that share price.
The amendment replaces the market share price standard with a fair value assessment that takes account of share price, asset value and earning values together, and applies the same standard to the purchase price for dissenting shareholders exercising appraisal rights. It also requires the board of a listed company to prepare and disclose a written opinion covering the purpose and expected effect of the transaction and the appropriateness of the merger price, and to obtain an evaluation from an external appraiser.
